🌍·1d agodiscovery
FDA approves Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner's National Priority Voucher pilot program, completing review in two months and expanding indications for community-acquired pneumonia and acute bacterial sinusitis i
Publisher
V
Vera Health
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Vera Health
- Region
- Global
- Scope
- discovery
- Published
- July 2, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Vera Health
Scope: discovery
Related coverage
More related coverage
Federal Register/-3446m ago
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Federal Register/-3446m ago
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications...
Federal Register/-3446m ago
Center for Scientific Review; Notice of Closed Meetings
Federal Register/-3446m ago
Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information
The Office of the Assistant Secretary for Health (OASH or we) is opening a public docket to solicit...